

TEXVAX Biotech

mRNA VACCINE PLATFORM

TEXAS INSTITUTE OF BIOTECHNOLOGY, EDUCATION & RESEARCH (TIBER)

VACCINESHEFA STARTUP LLC



Prepared by Cengiz Z. Altuntas, Ph.D
for Investors
February 2, 2021



Project attractiveness/actuality

The current world population is 7.8 billion as of February 2021 according to the most recent United Nations estimates elaborated by World meter. Every year all people should vaccines get at least 2 times. Thus **15.6 billion vaccines** in needed to eliminate pandemic. **SARS Co-2 gets mutations on its genome (RNA) That different vaccine would be produced to protect people.**

Also, There are more than **100 types of cancer**. Types of cancer are usually named for the organs or tissues where the cancers form. For example, lung cancer starts in cells of the lung, and brain cancer starts in cells of the brain.

In total, there were 3,987,800 new prostate cancer cases diagnosed in the United States between 2003 and 2020

mRNA VACCINE for cancer treatment is the new attractive field to treat cancer.

TEXVAX&Vaccinesheefa has experience on this field.ead with vaccines for cancer and Covid19

VACCINESHEFA STARTUP LLC

Vaccineshefa startup company operates in the field of prototype and serial production of COVID and CANCER vaccines, which are developed in universities, research centers, laboratories in the USA.

The **Vaccineshefa** team is among more than two dozen teams in US working on vaccines to combat the outbreak that has disrupted societies across the globe.

"You have need to have technologies and facilities that can produce several hundreds of millions of doses of the vaccine to protect those most in need,"

The **Vaccineshefa startup company** aims to collaborate with investors to develop vaccine work.

This Startup investments will help a biomedical startup for your country and your nation and all people, push ahead with vaccines for cancer and Covid-19

TEXVAX Biotech

VISION: A world where scientific innovations made possible through biotechnology conquer disease, sustain our environment, and healthfulness. To offer affordable, safe and effective healthcare solutions to combat mankind's dreaded illnesses and to thus eradicate or at least control their occurrence in the years to come.

MISSION: We seek to address the health care needs of the billion people in the emerging markets by driving innovation and being a frontrunner in research and development of new vaccines and bio-therapeutics. To advance biotechnology innovation by promoting sound public policy and fostering collaboration, both locally and globally.

Texas Institute of Biotechnology Education & Research (TIBER)

TIBER was founded in 2010 by North American University in Houston, Texas, USA. TIBER have several different platforms to develop effective solution to different problems in biomedical field. Thus, the same platform can be be applied to treat different human diseases such as Covid-19, cancer, Multiple Sclerosis (as an Autoimmune disease)

Prof. Dr. Cengiz Zubeyir Altuntas will be the key person to develop effective vaccine research program against to Covid-19 and others as the Chairman of TIBER and Partner of Vaccanisheefa Startup LLC .

STEPS OF THE VACCINE DEVELOPMENT FROM LAB TO MARKET

STEP:1

DEVELOPMENT OF
PROTOTYPE
m RNA VACCINE
IN THE LAB &
PRECLINICAL TEST
ON MICE

<https://jlabs.jnjinnovation.com/locations/jlabs-tmc>
HOUSTON TEXAS

STEP: 2

SYNTHESIZATION OF
m RNA VACCINE &
PREPARE VACCINE VIAL
ADDING LIPID
NANOPARTICLE
FOR CLINICAL TRIAL

At LONZA
<https://pharma.lonza.com/offerings/cell-and-gene-therapies/cGMP-manufacturing>
USA

STEP: 3

TEST
OF THE VACCINE
IN CLINICAL
TRIAL
IN KUWAIT
OR
USA

STEP: 4

PRODUCTION OF THE
VACCINE FOR MARKET
<https://pharma.lonza.com/offerings/cell-and-gene-therapies/cGMP-manufacturing>
USA

BUSINESS PLAN

- In the First year (2021-2022) TEXVAX BIOTECH will focus on developing a prototype of prophylactic or preventive **mRNA vaccine and developing** neutralizing antibodies for **Covid-19** to treat patients who already infected.
- The prototype of **mRNA vaccine** and also the neutralizing antibodies will be ready for **clinical trial on 2022.**
- TEXVAX BIOTECH will be launched at a **JLABS@TMC** Lab space **Johnson & Johnson Innovation** where Johnson & Johnson provide for start up companies.
(<https://jlabs.jnjinnovation.com/locations/jlabs-tmc>).
- After 2022 TEXVAX BIOTECH will focus on developing **mRNA CAR-T vaccine for cancer treatment** such as blood, **(AML), breast & ovarian cancer.**
 - **Car-T cell Vaccine will be ready in 2024 for clinical trial.**

mRNA VACCINE PLATFORM

PROPHYLACTIC OR PREVENTIVE VACCINES: A prophylactic, or preventative, vaccine involves introducing antigens into a person's body through different ways such as **mRNA vaccine**, **Recombinant Antigen Vaccine**, **viral vectors** etc. The goal is that the individual's immune system will create antibodies for those antigens and become immune to the associated illness.

TIBER is a biotechnology institute of North American University Houston Texas, USA that develops technologies and vaccines that stimulate and strengthen the immune system through active immunization by mRNA vaccine to fight against any kind of infection

1- Vaccine For Microorganism such as Covid-19. TIBER specializes in mRNA vaccines for use in the treatment of several infectious diseases, such as the Covid-19.

2-Vaccine For Cancer Immunotherapy: And also, the same platform will be applied to fight against cancer (Cancer Immunotherapy) through active immunization by mRNA vaccine to against organ or cancer specific antigens.

THERAPEUTIC VACCINE PLATFORM:

TIBER is a Research Institute specialized also in screening and developing human antibodies through molecular biology techniques in vitro for passive immunization for microbial disease such as Covid-19. Thus, TIBER set up Screening & Developing Human neutralizing Antibody Platform for producing neutralizing antibodies to treat viral disease.

Screening & Developing Human Covid-19 Neutralizing Antibody Platform

Therapeutic Vaccine For Microorganism: Neutralizing antibodies defend healthy cells by interfering with the biological function of an invading virus. These antibodies may be used therapeutically to treat someone currently fighting the disease and can be given to people who have heightened risk of exposure to **SARS-CoV-2**, such as healthcare workers.

ADVISORY BOARD MEMBERS



Maria Elena Bottazzi, Ph.D

Associate Dean, National School of Tropical
Medicine

Baylor College of Medicine

Houston, Texas United States

Professor

Departments of Pediatrics (Tropical Medicine)
and Molecular Virology and
Microbiology, Integrative Molecular
and Biomedical Sciences Program, and
Translational Biology and Molecular
Medicine Program
Baylor College of Medicine

Co-Director

Texas Children's Hospital Center for Vaccine
Development
Houston, Texas United States



Peter Jay Hotez, M.D., Ph.D

Dean for the National School of Tropical
Medicine

Baylor College of Medicine

Houston, United States

Professor

Departments of Pediatrics and Molecular
Virology and Microbiology
Baylor College of Medicine
Houston, Texas United States

Endowed Chair in Tropical Pediatrics

Texas Children's Hospital

Houston, Texas United States

Co-Director

Texas Children's Hospital Center for Vaccine
Development
Houston, Texas United States

Founding Editor in Chief

PLOS Neglected Tropical Diseases



Vincent K. Tuohy, PhD

Professor, Department of Molecular
Medicine, School of Medicine
Professor, Department of
Pathology, School of Medicine
Member, Hematopoietic and
Immune Cancer Biology Program,
Case Comprehensive Cancer Center



Larry S. Schlesinger, M.D.
President/CEO, Professor |
Host Pathogen
TEXAS BIOMEDICAL
RESEARCH INSTITUTE SAN
ANTONIO - TEXAS

EXPERT STAFF TO WORK FOR mRNA VACCINE PLATFORM

Scientist/Senior Scientist, Synthetic Biology (mRNA)

We are seeking a PhD Scientist or a Senior Scientist with deep expertise in the use of synthetic biology tools to design, engineer, and construct template DNAs for in vitro transcribed (IVT) mRNA production. Successful candidate will also synthesize, purify and test mRNAs in vitro in various human and murine cell lines.

Research Associate, Molecular Biology: TEXVAX Biotech is seeking an exceptional, highly motivated Research Associate to contribute to development of its mRNA 2.0 platform for therapeutic applications. The successful candidate will work as part of the team responsible for producing LNP formulated mRNAs and testing them in vitro and in vivo for preclinical studies. Candidate should be proficient in molecular biology workflows and wet lab techniques.

Research Associate, LNP Formulation

TEXVAX Biotech is seeking an exceptional, highly motivated Research Associate to contribute to the development of its mRNA 2.0 platform for therapeutic applications. The successful candidate will work as part of the team responsible for producing, characterizing, and testing LNP formulation for mRNA delivery. Candidate should be proficient in analytical chemistry and nanoparticle formulation workflows and wet lab techniques.

Senior Computational Biologist/Data Scientist, Bioinformatics

TEXVAX Biotech is seeking a highly motivated bioinformatics scientist to perform analysis of proteomics and next-generation sequencing data (mRNA-seq, ribo-seq). The successful candidate will work collaboratively with wet lab teams and will contribute to identification of cell specific sequence features.

Senior Technician: TEXVAX Biotech is seeking a MS Scientist in Biology as a technician to take care of the Lab equipment and reagents and also involve the experiments.

FUTURE PLAN:

After first year we will evaluate our success at LAB.

We expect to develop the prototype of the mRNA vaccine for clinical trial.

If we reached our target, then we will move forward to develop mRNA vaccine for cancer treatment (CAR-TCELL).

1-CHIMERIC T-CELL ANTIGEN VACCINE PLATFORM:

1. CAR For Cancer Treatment: CAR is first-in-class therapeutics in order to treat serious life-threatening cancers such as acute myeloid leukemia (AML) through Chimeric T-cell Antigen (CAR) technique in T-cell or National Killer Cell (NK-cell)

2. CAR For Autoimmune Disease Treatment: CAR is also, to engage in discovering, developing, manufacturing and marketing therapies for treating autoimmune disorders and neurodegenerative diseases such as Multiple Sclerosis (MS), in the United States as well as Internationally.

2-RECOMBINANT ANTIGEN VACCINE PLATFORM:

Recombinant Antigen Vaccine: TIBER is a biotechnology institute of North American University Houston Texas, USA | that develops technologies and vaccines that stimulate and strengthens the immune system through active immunization by mRNA vaccine and viral recombinant antigen vaccine to fight against any kind of infection.

1- Vaccine For Microorganism such as Covid-19. TIBER specializes in recombinant antigen nanoparticle vaccines for use in the treatment of several infectious diseases, such as the Covid-19.

2-Vaccine For Cancer Immunotherapy: And also, the same platform can be applied to fight against cancer (Cancer Immunotherapy) through active immunization by recombinant antigen vaccine to against organ or cancer specific antigens.

TIMELINE (18 Months) FOR THE PROJECT

TEXVAX BIOTECH will be founded on 2021 in Houston Texas at a [JLABS@TMC Lab space Johnson & Johnson Innovation](https://jlabstmc.com/locations/jlabs-tmc) where Johnson & Johnson provide for start up companies.

<https://jlabstmc.com/locations/jlabs-tmc>).

Prototype mRNA vaccine will be ready on July-2022
for Clinical trial

Neutralization antibodies will be ready on July-2022
for Clinical trial

- **Vaccinesheefa startup company** operates in the field of prototype and serial production of COVID and CANCER vaccines, which are developed in universities, research centers, laboratories in the USA.
 - The **Vaccinesheefa startup company** aims to collaborate with investors to develop vaccine work.
- WE CAN PROPOSAL TO THOSE WHO WANT TO INVEST IN THE VACCINESEEFa STARTUP COMPANY WITH THE NCDA CONTRACT BELOW.
 - **Project Detail Presentation** <https://global-trader.us/vaccaniseefa-startup-project/>
 - **Contact** globaltrade@gulfuscapital.com